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Objective. This study was performed to assess the cost-effectiveness of cyclooxygenase-2 (COX2)-selective inhibitor, non-se-
lective non-steroidal anti-inflammatory drugs (NSAIDs), and non-selective NSAID with proton pump inhibitors (PPIs) while 
considering upper and lower gastrointestinal (GI) safety in patients with rheumatoid arthritis (RA). Methods. A Markov model 
was used to estimate the costs and effectiveness. Estimates of therapeutic efficacy and upper/lower GI safety were based on re-
sults from large randomized controlled trials. The main outcome measure was cost effectiveness, based on the quality-adjusted 
life years (QALYs) gained. Safety parameters included clinical upper GI symptoms, uncomplicated ulcer, upper GI bleeding, 
upper GI perforation, clinical lower GI symptoms, lower GI bleeding, and lower GI perforation. Cost data were obtained from 
patients treated in a tertiary referral center in Korea. Results. The expected three year cost was 3,052,800 Korean won (KRW) 
for COX2-selective inhibitor, 3,170,800 KRW for nonselective NSAID, and 3,325,900 KRW for non-selective NSAID with PPI. 
QALYs were 2.87446, 2.85320, and 2.85815, respectively. The total cost for COX2-selective inhibitor use was lower than 
non-selective NSAID, but QALY was higher, indicating that the incremental cost effectiveness ratio of COX2-selective inhibitor 
is superior. Conclusion. COX2-selective inhibitor has reasonable cost-effectiveness adjusted for upper and lower GI toxicity for 
patients with RA in Korea. (J Rheum Dis 2017;24:27-34)
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INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) are 
one of the most frequently used drugs for the treatment of 
rheumatoid arthritis (RA) [1,2]. NSAIDs can cause sev-
eral adverse reactions, such as gastrointestinal (GI) com-
plications, azotemia, platelet dysfunction, allergic rhini-
tis, aggravation of asthma, skin rash, liver toxicity and 
bone marrow suppression [3,4]. Especially, NSAID-re-
lated GI complications are one of the most frequently en-
countered problems in clinical settings. Ten to sixty per-
cent of patients experience dyspepsia while taking 
NSAIDs, and 4% to 40% of patients suffer from ulcers in 
the upper GI tract. Five to fifteen percent of patients with 
RA may discontinue NSAIDs due to dyspepsia within 6 
months, and the mortality of NSAID-induced bleeding 
reaches up to 5% to 10% [5,6].
To reduce GI complications caused by NSAID uses, 
co-administration of proton pump inhibitor (PPI) with 
conventional NSAIDs, and replacement of conventional 
NSAIDs with selective cyclooxygenase-2 (COX-2) in-
hibitor, have been widely used. There are several reports 
showing that PPIs can prevent the development of gastric 
or duodenal ulcers through the inhibition of gastric acid 
secretion and co-administration of PPI with NSAIDs can 
reduce the risk of upper GI toxicity [7-10]. Another way 
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to prevent GI complications for patients taking NSAIDs 
for treatment of their arthritis is to replace non-selective 
NSAIDs with selective COX-2 inhibitors. The COX en-
zyme family consists of COX-1 and COX-2 isoenzymes. 
COX-1 is constitutionally expressed and controls normal 
physiologic reactions, such as maintenance of gastric mu-
cosal integrity. COX-2 is expressed only after inflam-
matory reaction and regulates pain and inflammation. 
Previous studies suggest that GI adverse events of con-
ventional NSAIDs are mediated through the inhibition of 
COX-1 enzyme, and selective COX-2 inhibitors could de-
crease the risk of GI complications of NSAID [11-13].
In the latest decade, there have been great developments 
in the treatment of RA, and various kinds of drugs have 
been used for RA treatment. However, NSAIDs are still 
being one of the most frequently prescribed agents for RA 
treatment in Korea [14], thus selecting more efficient and 
safer ways is as crucial as developing new agents for treat-
ment of RA. Most of previous studies on safety of NSAIDs 
have focused upper GI toxicity caused by NSAIDs use, but 
recent reports have addressed that NSAIDs use is also 
strongly related to the development of lower GI complica-
tions and that selective COX-2 inhibitor can reduce the 
incidence of NSAID induced lower GI complications 
[15-20]. 
Despite the increased interest in lowering GI toxicity of 
NSAID, there have been no pharmacoeconomic studies 
specifically focused on lowering GI toxicity of NSAIDs. 
This study was performed to assess the cost-effectiveness 
of a selective COX-2 inhibitor, non-selective NSAID, and 
non-selective NSAID with PPI with regards to GI safety in 
patients with RA. In this study, cost-effectiveness of each 
treatment strategy was compared considering lower GI 
toxicity as well as upper GI toxicity.
MATERIALS AND METHODS
Subject drugs
Non-selective NSAIDs and a selective COX-2 inhibitor 
were used to compare the cost and efficacy. Naproxen and 
meloxicam were chosen among non-selective NSAIDs 
because they are primarily used for treatment of RA in 
daily clinical practice of our institute, and celecoxib was 
chosen as a selective COX-2 inhibitor because it is the on-
ly selective COX-2 inhibitor approved for RA treatment in 
Korea. 
Evaluation framework
This study assumed that non-selective NSAIDs and 
COX2-selective inhibitor were equally effective for the 
control of RA in terms of anti-inflammatory and analgesic 
effects. Any GI toxicity such as peptic ulcers, ulcer bleed-
ing, and gastric or duodenal perforation was treated 
through hospitalization or on an outpatient basis. The 
treatment protocol of GI toxicity was based on clinical ex-
perience and textbook based algorithms [21]. If patients 
complain of clinical symptom alone that could not be pro-
ven by endoscopy, patients continued the NSAID treat-
ment with GI protective agents on an outpatient basis. If 
ulcers were detected by endoscopy, NSAID was dis-
continued and GI protective agents or PPI was used for 8 
weeks or longer. If GI bleeding was observed in addition 
to ulcers, then NSAID use is stopped and patients are 
hospitalized for endoscopic hemostasis. GI protective 
agents or PPI should be maintained for 8 weeks. If there 
were perforation, NSAID was discontinued, and surgical 
treatment was considered depending on the severity. If 
there were any GI problems in patients who were treated 
with non-selective NSAID, NSAIDs were switched to a 
COX2-selective inhibitor (Figure 1).
A Markov model with a 12-week transition cycle was 
used to estimate the cost and effectiveness of each treat-
ment groups with a 3-year time horizon, and comparative 
parameters were separated into three groups: COX2-se-
lective inhibitor group, non-selective NSAID group, and 
non-selective NSAID with PPI group [22]. Modeling was 
conducted using TreeAge Pro 2009 software (TreeAge 
Software, Inc., Williamstown, MA, USA).
Input parameters
Variables for transition probability were improvement 
in RA symptoms and development of GI toxicity. Estimates 
of therapeutic efficacy were based on data from the 
Celecoxib Long-Term Arthritis Safety Study (CLASS) 
clinical study [19]. CLASS study is the largest random-
ized controlled trial which compared GI toxicity of cele-
coxib with NSAID for osteoarthritis (OA) and RA patients. 
A total of 7,968 outpatients aged 18 years or older, diag-
nosed as having RA or OA evident for at least 3 months 
and were expected to require continuous treatment with 
an NSAID for the duration of the trial received at least 1 
dose of medication. Of these, more than 20% of the pa-
tients were taking low-dose aspirin (≤325 mg/d). In 
CLASS study, efficacy of each drug strategy assessed by 
patient’s global assessment of arthritis after 26 week use 
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Figure 1. Part of a decision tree for cost-effectiveness of rheumatoid arthritis treatment. Three strategies are modeled by non-
steroidal anti-inflammatory drug (naproxen or meloxicam), celecoxib, and NSAID with PPI. NSAID: non-steroidal anti-in-
flammatory drug, PPI: proton-pump inhibitor, GI: gastrointestinal, UGI: upper gastrointestinal, LGI: lower gastrointestinal, EGD:
esophagogastroduodenoscopy, MED: medication, CT: computed tomography. 
of COX2-selective inhibitor 200 mg twice a day (bid), di-
clofenac 75 mg bid, and ibuprofen 800 mg three times a 
day. Improvement in arthritis was observed in 1,512 of 
3,987 patients of celecoxib group (38%) and in 1,441 of 
3,981 patients (36%) of diclofenac and ibuprofen groups. 
There is no difference in drug efficacy between these two 
groups. Thus, we assumed the improvement rate of 
COX2-selective inhibitor as 38%, and the improvement 
rate of NSAID as 36%. We assumed that PPI did not influ-
ence symptom improvement effect of NSAID, and thus 
we assumed the improvement rate of NSAID plus PPI 
group to be the same as NSAID group (36%) (Table 1). 
Safety parameters included clinical upper GI symptoms 
such as reflux or dyspepsia, uncomplicated ulcer, upper 
GI bleeding, and upper GI perforation. Clinical lower GI 
symptoms such as diverticulitis or diarrhea, lower GI 
bleeding, and lower GI perforation were included. The 
complication probabilities of non-selective NSAID group 
and COX2-selective inhibitor group were cited from 
CLASS study after time-frame adjustment. Since there is 
no study with exactly matching complication probability 
of NSAID plus PPI group, and we substituted the same 
data with COX2-selective inhibitor group by author’s 
best estimate. GI toxicity of NSAID with PPI is known to 
be equal or higher than COX2-selective inhibitor treat-
ment [23]. Thus, we conservatively assumed that the GI 
toxicity of the two groups were equal. The prevention ef-
fect of lower GI toxicity of PPIs has not been proved. 
Thus, the toxicity of NSAID with PPI might be regarded 
as the same as that of the NSAID alone strategy (Table 1).
The variables for effectiveness were utility of health 
states presented as quality of life (QOL) scores. The QOL 
scores of each health status were based on data from 
searched literature [22]. A utility of 0 for death and a utili-
ty of 1 for health states of complete recovery from RA 
were assumed. A utility of 0.688 for a patient with RA, 
0.504 for health states of clinical upper GI events, 0.38 for 
uncomplicated upper GI ulcer, 0.312 for upper GI bleed-
ing and 0 for upper GI perforation were quoted. QOL 
scores of lower GI complications were estimated to be 
equal to QOL scores of upper GI complications, because 
there was no prior cost-effectiveness study on lower GI 
complications (Table 2).
Data of medication and monitoring costs were derived 
from the database of the Health Insurance Review and 
Assessment Services of 2011∼2012. Cimetidine was chosen 
as primarily used GI protective agent and omeprazole as 
primarily used PPI. Monitoring cost was physician fee at 
the outpatient clinic, and distribution cost was the drug 
cost at the pharmacy. The cost for treating each GI event 
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Table 2. Utility of health status
Health status QOL Source
RA 0.688 [26]
  Complete recovery from RA 1
  Death 0
Clinical upper GI events 0.504 [26]
Uncomplicated upper GI ulcer 0.38 [26]
Upper GI bleeding 0.312 [26]
Upper GI perforation 0 [26]
Clinical lower GI events 0.504 Author’s best estimate*
Lower GI bleeding 0.312 Author’s best estimate*
Lower GI perforation 0 Author’s best estimate*
QOL: quality of life, RA: rheumatoid arthritis, GI: gastroin-
testinal. *The QOL scores of lower GI complications were 
estimated to be equal to those of upper GI complications.
Table 1. Health transition probability
Health transition Probability (%) Source
Improve RA
  NSAIDs 36 CLASS study*
  Celecoxib 38 CLASS study*
  NSAIDs+PPI 36 CLASS study*




  NSAIDs 0.362 CLASS study*
  Celecoxib 0.308 CLASS study*
  NSAID+PPI 0.308 Author’s best estimate†
Uncomplicated ulcer
  NSAIDs 0.169 CLASS study*
  Celecoxib 0.110 CLASS study*
  NSAID+PPI 0.110 Author’s best estimate†
UGI Bleeding
  NSAIDs 0.116 CLASS study*
  Celecoxib 0.058 CLASS study*
  NSAID+PPI 0.058 Author’s best estimate†
UGI Perforation
  NSAIDs 0.000 CLASS study*
  Celecoxib 0.000 CLASS study*
  NSAID+PPI 0.000 Author’s best estimate†
Clinical LGI events
  NSAIDs 4.757 CLASS study*
  Celecoxib 3.387 CLASS study*
  NSAID+PPI 4.757 Author’s best estimate‡
LGI Bleeding
  NSAIDs 0.379 CLASS studya*
  Celecoxib 0.197 CLASS studya*
  NSAID+PPI 0.379 Author’s best estimate‡
LGI Perforation
  NSAIDs 0.012 CLASS study*
  Celecoxib 0.000 CLASS study*
  NSAID+PPI 0.012 Author’s best estimate‡
RA: rheumatoid arthritis, NSAIDs: non-steroidal anti-inflam-
matory drugs, PPI: proton pump inhibitor, UGI: upper gast-
rointestinal, LGI: lower gastrointestinal, CLASS: Celecoxib 
Long-Term Arthritis Safety Study, GI: gastrointestinal. *CLASS 
clinical study. †GI toxicitiy of NSAID with PPI might be equal
with that if celecoxib treatment. ‡PPI could not prevent lower
GI complications. 
was determined by the treatment cost at our institute, a 
tertiary referral center in Seoul, Korea. Based on the treat-
ment protocol of any GI toxicity such as peptic ulcers, ul-
cer bleeding, and gastric or duodenal perforation, the re-
source use was measured to estimate the cost of treating 
GI toxicity: hospitalization, medication, imaging tests, 
laboratory tests, procedures or surgery, and other medical 
treatment. The number of units consumed by each pa-
tient was multiplied by the cost per unit of each resource 
to estimate the direct costs for each patient. The cost data 
obtained in Korean won (KRW) are shown in Table 3.
Incremental cost effectiveness ratio 
In clinical practice, a realistic option may be to compare 
a new treatment strategy with the standard method. 
Thus, the difference in these costs would be of interest to 
the decision maker. The term ‘incremental costs’ is often 
used to refer to the difference between alternatives. The 
incremental cost effectiveness ratio (ICER) is the result 
of incremental cost of a new treatment to standard treat-
ment divided by incremental effectiveness of new treat-
ment to standard treatment [24]. 
The primary outcome measure was based on quality ad-
justed life years (QALY) gained, which is used in most 
cost effectiveness analysis studies [25,26]. Utilities of 
health status were based on quality of life weight scores 
through a detailed review of the medical literatures. 
RESULTS
Incremental cost effectiveness ratio (ICER)
Medication, monitoring costs, distribution cost and cost 
for treating each GI event were included in total cost. The 
expected 3 year total cost was 3,052,800 KRW for COX2-se-
lective inhibitor treatment, 3,170,800 KRW for non-se-
lective NSAID, and 3,325,900 KRW for non-selective NSAID 
with PPI. The direct medical cost of the COX2-selective 
inhibitor treatment group during routine management 
was also proven to be significantly lower. QALY for 
COX2-selective inhibitor treatment was 2.87446, for 
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Table 3. Estimated costs of treatment for gastrointestinal complications
Data Cost (USD) Source
Drug cost*
  Celecoxib 200 mg bid 44 Health Insurance Review and Assessment Services
  Naproxen 500 mg bid 9 Health Insurance Review and Assessment Services
  Meloxicam 7.5 mg bid 19 Health Insurance Review and Assessment Services
  Omeprazole 20 mg qd 23 Health Insurance Review and Assessment Services
  Cimetidine 800 mg qd 4 Health Insurance Review and Assessment Services
Monitoring cost 10 National Health Statistical Yearbook‡
Distribution cost† 11 National Health Statistical Yearbook‡
GI complications
  Clinical UGI event 137 Hospital data§
  Uncomplicated ulcer 137 Hospital data§
  UGI bleeding 1,329 Hospital data§
  UGI perforation 6,134 Hospital data§
  Clinical LGI event 1,400 Hospital data§
  LGI bleeding 3,163 Hospital data§
  LGI perforation 14,010 Hospital data§
USD: United States dollar, bid: twice per day, qd: once per day, GI: gastrointestinal, UGI: upper gastrointestinal, LGI: lower 
gastrointestinal. *Drug costs were calculated over a 4 week period. †Distribution costs were calculated over a 12 week period. 
‡National Health Insurance Corporation, Health Insurance Review & Assessment Services; 2011∼2012 National Health 
Statistical Yearbook. §Obtained from patients who had been treated in a tertiary referral center, Seoul, South Korea.
Table 4. Cost effectiveness of three treatment strategies
Strategy Total cost (KRW) Effectiveness (QALY) ICER
Celecoxib 3,052,800 2.87446 Dominant*
NSAID 3,170,800 2.85320 Dominated†
NSAID+PPI 3,325,900 2.85533 Dominated†
KRW: Korean won, QALY: quality-adjusted life year, ICER: incremental cost effectiveness ratio, NSAID: non-steroidal 
anti-inflammatory drug, PPI: proton-pump inhibitor. *The intervention costs less and is at least as effective as the comparator. †The
intervention costs more and is no more effective than the comparator.
nonselective NSAID 2.85320, and for non-selective NSAID 
with PPI 2.85533. The total cost for COX2-selective in-
hibitor was lower than non-selective NSAID but QALY 
was higher by 0.02126, and thus the ICER for COX2-se-
lective inhibitor in comparison with non-selective NSAID 
showed dominance (Table 4). This result suggests that 
COX2-selective inhibitor can be considered to be cost 
effective. 
Sensitivity analyses
Sensitivity analysis was performed for utility value. We 
substituted minimum zero to maximum 0.688 for health 
status of lower GI complications. After substitution, cost 
of COX2-selective inhibitor increased to 3,079,400 KRW, 
and QALYs rather increased or decreased (2.82900∼
2.89100). The result also showed COX2-selective in-
hibitor strategy to be dominant ICER over non-selective 
NSAID or non-selective NSAID with PPI strategies. 
DISCUSSION
In the present study, we performed pharmacoeconomic 
analysis on therapeutic efficacy and toxicities involving 
both upper and lower GI tracts of NSAIDs and found that 
the use of COX-2 selective inhibitor has a reasonable 
cost-effectiveness for patients with RA in Korea. Although 
the individual cost for COX-2 selective inhibitor is higher 
than non-selective NSAIDs and there is no evident differ-
ence in therapeutic efficacies between them, the use of 
COX-2 selective inhibitor appears to be economically at-
tractive compared to non-selective NSAID alone or 
non-selective NSAID with PPI with regards to the devel-
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opment of upper and lower GI complications.
In the present study, several basic assumptions were 
made by authors’ best estimate. First, we hypothesized 
that treatment with non-selective NSAID and PPI would 
show very similar upper GI toxicity rate with COX-2 se-
lective inhibitor group. Although some authors sug-
gested that the incidence of upper GI toxicities caused by 
the use of non-selective NSAID with PPI were higher than 
the use of selective COX-2 inhibitors [2], there is no ex-
actly matching study on complication probability of 
non-selective NSAID with PPI group versus COX-2 se-
lective inhibitor group, thus we made a conservative esti-
mate of the upper GI toxicity rate of NSAID plus PPI 
group. Second, we assumed that the protective effect of 
PPI does not influence the incidence and severity of lower 
GI toxicities and that the development of lower GI tox-
icity caused by non-selective NSAID with PPI was re-
garded as same as that caused by non-selective NSAID 
alone strategy in this study. It has been reported that 
NSAID is equally associated with upper and lower GI 
events [17,18,20]. The pathogenesis of NSAID-induced 
enteropathy is initiated by the inhibition of oxidative 
phosphorylation in the enterocytes exposed to the in-
gested NSAID and further exacerbated by contact through 
enterohepatic circulation, and prominent apoptosis com-
bined with increased intraepithelial lymphocyte counts 
are characteristic features of this condition [27,28]. Lower 
GI toxicity of NSAIDs in the small bowel and colon may 
be independent of acid secretion and the use of anti-secre-
tary agents including PPI does not prevent lower GI com-
plications as compared with the known protective effect 
for upper GI complications [29]. To eliminate the effect of 
PPI on lower GI toxicity, we performed sensitivity analy-
sis varying utility estimates, and the recalculated results 
did not show difference. This indicates that our results 
are robust to the working assumptions on utility parameters.
The price of COX-2 selective inhibitor has been set high, 
thus it is needed to assess the clinical benefits, costs for 
adverse events, and cost-effectiveness of COX-2 selective 
inhibitor compared with non-selective NSAIDs. Most of 
previous studies focused on pharmacoeconomic analysis 
regarding upper GI toxicities of NSAID uses. However, 
recent reports showed that a very high incidence of lower 
GI damage has been reported in young, healthy, human 
subjects taking both a non-selective NSAID and a PPI, in-
dicating that the PPI conferred little protection to lower 
GI tracts, which are major sites of NSAID-induced bleed-
ing and perforation [30-32]. And several studies showed 
that COX-2 selective inhibitor could be a better choice to 
reduce mucosal lesions of the small bowel compared with 
non-selective NSAID with PPI [33,34]. Several other eco-
nomic evaluations of COX-2 selective inhibitor versus 
NSAID or NSAID plus PPI have been published, all with 
very different results [35-40]. In the present study, we an-
alyzed the cost effectiveness of NASID uses associated 
with the risk of upper and lower GI complications and 
found that the use of COX-2 selective inhibitor shows 
reasonable cost effectiveness over non-selective NSAID 
alone and non-selective NSAID with PPIs. To the best of 
our knowledge, this is the first study that evaluated cost 
effectiveness of various NSAIDs use strategies for treat-
ment of RA with regards to both upper and lower GI tract 
toxicities. 
There are several limitations in the present study. We 
performed a detailed search of the medical literatures, 
and there were many differences in patient groups, drug 
regimens, drug doses, and definition of adverse events 
among the studies, which might influence the rate of GI 
toxicities. There was no prospective study about GI com-
plications with the same NSAID, thus we extracted most 
of our data from the CLASS study. There have been diffi-
culties with the interpretation of the CLASS study be-
cause of preferential withdrawal of patients with GI risk 
factors from the NSAID treatment arm. Therefore, a limi-
tation of the present analysis was that the economic per-
spective, depending on the GI risk of the individual pa-
tient was not evaluated. Although it has been suggested 
that COX-2 selective inhibitor may increase the risk of 
cardiovascular thromboembolic events via inhibition of 
vascular prostacyclin synthesis without a corresponding 
inhibition of platelet thromboxane, no such increase was 
evident in the CLASS study. This study did not include 
cardiovascular thrombotic adverse events that NSAID 
uses can cause [13,41]. Considering these complications, 
this study may lead to different conclusion and further 
studies are expected to consider overall complications in-
cluding cardiovascular events. In addition, we did not in-
clude the indirect cost in this cost-effectiveness analysis. 
Further work is needed to collect real world evidence in-
cluding GI toxicity event in Korea as well as indirect cost.
CONCLUSION
The ICER of COX-2 selective inhibitor was superior to 
those of non-selective NSAID alone and non-selective 
NSAID with PPI. These data showed that COX-2 selective 
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inhibitor had reasonable cost effectiveness for patients 
with RA in Korea. There have been no pharmacoeco-
nomic studies comparing cost effectiveness of various 
NSAIDs strategies with regards to entire GI tract 
complications. To make a precise comparison about cost 
effectiveness among COX-2 selective inhibitor, non-se-
lective NSAID alone and non-selective NSAID with PPI, 
more controlled prospective studies are warranted to 
compare the therapeutic efficacies, GI complications, and 
cardiovascular complications.
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